Talaris Therapeutics, Inc. filed a definitive proxy statement with the SEC in connection with its merger with Tourmaline Bio, Inc., and settled a litigation matter with ImmunoFree Inc. for $4 million.
AI Assistant
TOURMALINE BIO INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.